Harrow, Inc. Convertible Debt, Noncurrent
Harrow, Inc. (HROW) had Convertible Debt, Noncurrent of $914.00 thousand as of 2016-09-30, per its 10-Q filed 2016-11-14.
Discontinued › Balance Sheet › Liabilities › Long-Term Debt and Lease Obligation › Long-Term Debt, Excluding Current Maturities
us-gaap:ConvertibleDebtNoncurrent · last filed 2016-11-14
- 2016-09-30: Convertible Debt, Noncurrent $914.00K.
- 2016-06-30: Convertible Debt, Noncurrent $758.00K.
| Period end | Convertible Debt, Noncurrent |
|---|---|
| 2016-09-30 | $914.00K 10-Q · filed 2016-11-14 |
| 2016-06-30 | $758.00K 10-Q · filed 2016-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |